Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

NCT02092909 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
31
Enrollment
INDUSTRY
Sponsor class

Stopped Lack of efficacy

Conditions

Interventions

Sponsor

Idera Pharmaceuticals, Inc.